Sterling Private Medical Review: Following the GLP-1 Care Handoffs

01One brand, several responsible parties

Sterling presents itself as a private concierge telehealth practice for weight, hormones and healthy aging, serving men and women. It promotes a continuing physician relationship and says GLP-1 programs can be booked online, while other services are arranged directly with the physician. Hormone optimization is also advertised. That presentation suggests coordinated access, but it should not be read as establishing that Sterling itself employs the treating professional or performs every part of care.

The legal description is narrower: Sterling facilitates access to independent clinical providers and state-licensed compounding pharmacies. The site describes those providers as U.S. board-certified, but the consulted documentation does not name the clinicians, medical groups or pharmacies sufficiently to verify those credentials. Its terms expressly say Sterling does not practice medicine, provide clinical care, prepare or dispense medication, or direct the partners' professional judgment.

That division is not inherently a verdict on care quality; it is a map of responsibility. Before enrolling, ask for the treating medical group's name, the clinician's credentials and the dispensing pharmacy's identity, plus the contact route for each. Our guide to clinicians and telehealth platforms explains why the organization collecting payment may differ from the organization responsible for a clinical decision.

02Intake is a request for evaluation, not an approval

The advertised starting point is a short online assessment covering health goals and basic medical history. A licensed clinician reviews that information and, if clinically appropriate, creates a personalized plan and coordinates care. Access requires registration and an account with a username and password. The terms make the prescription gate explicit: patients must complete a consultation, the provider must determine the product is appropriate, and the provider must issue a prescription.

Sterling's semaglutide and tirzepatide pages describe candidates as adults 18 or older with a BMI of at least 27, or at least 25 with weight-related conditions. These are the site's published criteria, not a general eligibility recommendation. Its BMI calculator is labeled educational, with eligibility left to a licensed provider. The semaglutide page also lists exclusions involving medullary thyroid carcinoma or MEN 2 history, pregnancy, breastfeeding, pregnancy plans, active pancreatitis and untreated severe gastrointestinal disease.

Geography is another intake condition. The terms require adulthood—or the local age of majority if higher—and physical presence during consultation in the same state as the account's shipping address. Although Sterling advertises national reach, availability remains subject to state regulations and can change. No operational state-by-state list was established in the consulted documentation. Confirm availability for the specific program before assuming that a mailing address alone establishes access.

03The prescription-to-pharmacy handoff needs names and product details

Sterling describes compounded medication prepared by partner compounding pharmacies in the United States. Its disclaimer places custom-compounded prescribing in circumstances where commercially available treatments do not meet an individual's needs. The terms also impose a meaningful channel restriction: purchasing a service that includes a prescription requires accepting fulfillment through a pharmacy accessible through the platform and waiving the ability to choose another pharmacy for that purchase.

The Microdose offering is less specifically described than the two injection programs. Sterling markets it to people near their goal weight, those who tolerated standard GLP-1 treatment poorly and those incorporating it into a broader hormone or healthy-aging plan. However, the consulted documentation does not establish its active ingredient or route. Those marketing descriptions do not establish improved tolerability or outcomes for the actual product a patient might receive.

FDA states that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. That fact alone does not prove clinical inequivalence. FDA recommends compounded drugs when an individual's medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Use the pharmacy-handoff questions to obtain the product, pharmacy and instruction details rather than relying on an ingredient name alone.

04Delivery promises do not establish an arrival date

Sterling advertises discreet delivery directly to the home in temperature-controlled, unmarked packaging. Its treatment description says medication is shipped on a structured cadence, but does not quantify that cadence. The documentation does not establish the quantity in each shipment, its exact duration, or the time needed for clinical review, pharmacy preparation, dispatch or arrival. A recurring payment date therefore cannot be treated as a confirmed shipment or delivery date.

There is also a specific packaging limitation: the terms say prescriptions fulfilled by partner pharmacies may not use child-resistant packaging and that prescription products will not be dispensed in child-resistant containers. That deserves attention before a package reaches the household. Ask the pharmacy what containers and storage instructions accompany the actual preparation, and ask Sterling which party handles damaged packages, delayed deliveries or questions about temperature control.

FDA explicitly recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern. Sterling's packaging claim does not replace that advice or establish how every shipment will arrive. Our guide to warm injectable deliveries provides context for that conversation. The consulted Sterling pages do not document a specific replacement policy or resolution timetable for such deliveries.

05A bundled price still crosses three organizations

The advertised starting prices are $169 per month for semaglutide injection, $199 per month for tirzepatide injection and $129 per month for GLP-1 Microdose. Each listing includes medication, supplies, discreet delivery and concierge care with check-ins. Sterling says the final price is confirmed after consultation. The Microdose listing does not establish its ingredient or route, so its lower advertised price is not a like-for-like comparison with the named injection programs.

The homepage describes a flat monthly price including medication, provider care and concierge support, without insurance required. The semaglutide page additionally promises no consultation charges or dose-change surcharges. Meanwhile, the terms explain that the subscription bundles pharmacy fees, medical-group fees and Sterling's platform charge; Sterling collects the third-party portions on their behalf. That explains payment collection, but does not make Sterling the clinical provider or dispensing pharmacy.

For recurring monthly orders, the terms authorize an immediate charge and another every 30 days until cancellation, with electronic notice five to seven days before a scheduled transaction and a receipt afterward. Thirty days is not necessarily a calendar month. The documentation does not explain what raises the final price above the advertised starting amount, whether laboratory tests or in-person care are included, or whether shipping carries a separate fee. Obtain the individualized total and inclusions before authorizing recurring billing.

06Follow-up is advertised; clinical response times are not

Sterling describes structured check-ins intended to adjust the protocol and broader plan according to a patient's response. Between reviews, patients can message the care team through a private portal, advertised as available around the clock. These are useful access features on paper. However, the consulted documentation does not quantify the check-in schedule or say when a message requiring clinical judgment will reach the prescribing professional rather than a concierge support representative.

The contact page lists support@sterlingprivatemedical.com and (475) 290-6731, alongside 24/7 secure messaging. It also says the team will respond to contact-form messages within 24 hours. That form-response promise is distinct from guaranteed medical review, prescription approval or pharmacy action within 24 hours. Before enrollment, ask how administrative questions are separated from medication concerns, who covers the prescriber's absence and how patients obtain follow-up when a pharmacy question requires clinical input.

NIDDK describes follow-up as attention to treatment response and tolerability, not simply continued payment. FDA has also received reports of errors measuring or administering compounded medication, some involving hospitalization. Those reports are not a Sterling-specific event rate. They reinforce the practical value of confirming who explains the dispensed product's instructions and answers uncertainties. A review cannot substitute for the prescriber or pharmacist, and should not be used to calculate or adjust a dose.

07Ending payments and ending care are different handoffs

Sterling's cancellation language is materially inconsistent. Treatment pages say memberships may be canceled with 30 days' notice before the next billing cycle. The terms instead permit cancellation by switching off auto-refill in the user portal up to 48 hours before monthly processing. These are different deadlines and potentially different procedures. The consulted documentation does not resolve which governs a particular enrollment, so neither should be silently substituted for the other.

Refund boundaries are separate. The treatment page says consultations, medical visits and fulfilled prescriptions are nonrefundable once services begin or medication is processed. Stopping future renewals therefore does not establish entitlement to recover an earlier charge. Before purchasing, request written confirmation of the applicable cancellation deadline, the exact processing date and what happens if a cancellation request coincides with clinical work or pharmacy processing.

For care continuity, also ask what access remains after renewal stops: whether messages can still be sent, who answers questions about an already-dispensed prescription and how records can be obtained for another clinician. The consulted pages do not settle those transition details. Our guide to changing a program or stopping payments distinguishes administrative cancellation from clinical planning without recommending that an individual discontinue treatment.

08Privacy needs the same responsibility map as treatment

The semaglutide page says medical information is shared only with the physician and dispensing pharmacy, alongside a broad promise not to sell or share data. The terms add important organizational context: Sterling is not a HIPAA covered entity, although it may act as a business associate of a pharmacy or medical group in certain circumstances. A secure portal claim does not, by itself, explain which organization's privacy duties apply to each category of information.

Sterling's California notice says some personal information may be disclosed to third parties for advertising delivery, measurement and improvement, and that these disclosures may count as a sale or sharing under California law. That notice and the treatment page use different categories and contexts; they should not be collapsed into a claim that medical records are sold. They do, however, warrant clarification of how browsing, marketing, account and clinical information are handled.

Ask for the privacy notice applicable to the treating medical group and pharmacy, along with an explanation of Sterling's advertising disclosures and available choices. The consulted terms contained an omitted intermediate section, and a separate HIPAA notice was not reviewed. Consequently, this review cannot establish a complete data-flow map. The sensible documentary conclusion is limited: the public privacy promise is simpler than the more qualified picture presented across the legal documents.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Sterling Private Medical — treatments/semaglutide ↗
4. Sterling Private Medical — official website ↗
5. Sterling Private Medical — about ↗
6. Sterling Private Medical — contact ↗
7. Sterling Private Medical — privacy ↗
8. Sterling Private Medical — terms ↗
9. Sterling Private Medical — treatments/tirzepatide ↗
10. Sterling Private Medical — treatments/glp 1 microdose ↗

Continue reading

• Who Provides Your Care When You Use a Telehealth Platform?
• From Prescription to Dispensing: Questions for the GLP-1 Pharmacy Handoff
• When Injectable Medicine Arrives Warm: Reading the FDA Advice
• What Ongoing GLP-1 Support Actually Means
• Before You Stop Payments or Change a GLP-1 Program, Ask Who Still Owns Your Care